Ocain Tim 4
4 · ENANTA PHARMACEUTICALS INC · Filed Oct 2, 2018
Insider Transaction Report
Form 4
Ocain Tim
Senior Vice President
Transactions
- Exercise/Conversion
Common Stock
2018-10-01$32.27/sh+10,000$322,700→ 31,127 total - Sale
Common Stock
2018-10-01$82.04/sh−3,500$287,142→ 27,627 total - Sale
Common Stock
2018-10-01$83.47/sh−6,219$519,127→ 21,408 total - Sale
Common Stock
2018-10-01$84.02/sh−14,677$1,233,113→ 6,731 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-10-01−15,000→ 0 totalExercise: $19.98Exp: 2023-10-29→ Common Stock (15,000 underlying) - Exercise/Conversion
Common Stock
2018-10-01$19.98/sh+15,000$299,700→ 21,127 total - Sale
Common Stock
2018-10-01$85.30/sh−604$51,521→ 6,127 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-10-01−10,000→ 60,000 totalExercise: $32.27Exp: 2024-01-30→ Common Stock (10,000 underlying)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2018.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $81.84 to $82.21, inclusive.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $82.77 to $83.76, inclusive.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.77 to $84.73, inclusive.
- [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.915 to $85.67, inclusive.
- [F6]100% of the shares subject to this option are fully vested and exercisable.